Literature DB >> 1501783

Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia.

J Pratt1, J Rataud, F Bardot, M Roux, J C Blanchard, P M Laduron, J M Stutzmann.   

Abstract

Riluzole (2 amino 6-trifluoromethoxybenzothiazole), when administered at 4 and 8 mg/kg i.p., 0.5, 4.5, 24 and 28 h after the initiation of ischaemia, significantly reduced the prevalence of slow wave, and increased the proportion of higher frequency activity seen in the quantified electrocorticogram (ECoG), during the weeks that followed a 6 min bilateral occlusion of the common carotid arteries in the Mongolian gerbil. In focal ischaemia, provoked in Fischer rats following the occlusion of the middle cerebral artery, administration of riluzole (8 mg/kg) at 30 min and 24.5 h post occlusion significantly reduced the volume of infarcted cortex. These activities of riluzole could be related to its inhibition of sodium channel activity, which in turn inhibits glutamate release.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501783     DOI: 10.1016/0304-3940(92)90108-j

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

Review 1.  The search for neuroprotective strategies in stroke.

Authors:  Gary H Danton; W Dalton Dietrich
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

2.  Influence of hydrocortisone on the mechanical properties of the cerebral endothelium in vitro.

Authors:  Sebastian Schrot; Christian Weidenfeller; Tilman E Schäffer; Horst Robenek; Hans-Joachim Galla
Journal:  Biophys J       Date:  2005-09-23       Impact factor: 4.033

3.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

4.  The effect of Riluzole on functional recovery of locomotion in the rat sciatic nerve crush model.

Authors:  M B Ghayour; A Abdolmaleki; M Behnam-Rassouli
Journal:  Eur J Trauma Emerg Surg       Date:  2016-06-09       Impact factor: 3.693

5.  Functional identification of activity-regulated, high-affinity glutamine transport in hippocampal neurons inhibited by riluzole.

Authors:  Jeffrey D Erickson
Journal:  J Neurochem       Date:  2017-05-18       Impact factor: 5.372

6.  Effects of riluzole on electrically evoked neurotransmitter release.

Authors:  T Jehle; J Bauer; E Blauth; A Hummel; M Darstein; T M Freiman; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 7.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

8.  A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids.

Authors:  M Fink; F Lesage; F Duprat; C Heurteaux; R Reyes; M Fosset; M Lazdunski
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

Review 9.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  TREK-1, a K+ channel involved in neuroprotection and general anesthesia.

Authors:  C Heurteaux; N Guy; C Laigle; N Blondeau; F Duprat; M Mazzuca; L Lang-Lazdunski; C Widmann; M Zanzouri; G Romey; M Lazdunski
Journal:  EMBO J       Date:  2004-06-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.